As part of CRA’s issues leadership initiative to challenge industry thinking on rare diseases, we assembled a panel of CRA experts to discuss the opportunities and challenges posed by the latest therapeutic breakthroughs in conditions that affect fewer than one in 2,000 people. Neil Turner moderates a discussion with Greg Bell, Kevin Brubacher, Ned Kitfield, Cécile Matthews, and Tim Wilsdon.
Analytics for clinical development strategy: Tools and opportunities
In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their...